Hykin P, Prevost AT, Vasconcelos JC, et al. - In this investigation involving 463 candidates [mean (SD) age of 69.1 (13.0) years], researchers ascertained if intravitreal aflibercept or bevacizumab vs ranibizumab results in a noninferior mean change in a vision at 100 weeks for eyes with CRVO-related macular edema. This research was conducted in 44 UK National Health Service ophthalmology departments from December 12, 2014, to December 16, 2016. The study participants were randomized (1:1:1) to obtain repeated intravitreal injections of ranibizumab (0.5 mg/0.05 mL) (n = 155), aflibercept (2.0 mg/0.05 mL) (n = 154), or bevacizumab (1.25 mg/0.05 mL) (n = 154) for 100 weeks. According to this randomized clinical trial, aflibercept treatment was noninferior (no worse than) ranibizumab treatment at 100 weeks and the results for bevacizumab vs ranibizumab were not noninferior (ie, inconclusive vs the ranibizumab group). This is important information that should be considered before treating such cases by ophthalmologists.